华大智造2025年净利预亏2.21亿元至2.73亿元，同比减亏

Core Viewpoint - The company, BGI Genomics (华大智造), forecasts a significant reduction in net losses for 2025, projecting a net profit attributable to shareholders between -2.21 billion to -2.73 billion yuan, which represents a year-on-year improvement in losses by 3.28 billion to 3.8 billion yuan, equating to a reduction of 54.56% to 63.22% compared to the previous year [1] Group 1 - The company focuses on the research, production, and sales of instruments and reagents in the life sciences and biotechnology sectors [1] - For 2025, the company aims to leverage the dual trends of multi-omics integration and AI deep empowerment, driving continuous development in the life sciences field [1] - The company plans to consolidate its operations into three main business segments: long-read sequencing, intelligent automation, and multi-omics [1] Group 2 - The company has implemented a series of measures aimed at improving quality and efficiency, including enhancing labor productivity, focusing on R&D, and managing marketing expenses throughout the cycle, which has led to a reduction in costs compared to the same period last year [2] - Currency fluctuations have resulted in an increase in foreign exchange gains from monetary items held by the company compared to the previous year [2] - The company has reversed tax provisions related to uncertainties from previous years, leading to a decrease in income tax expenses year-on-year [2] - The company has made impairment provisions for various assets in accordance with accounting standards and policies, based on the principle of prudence [2]